The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors.
 
Yara Abdou
Honoraria - Clinical Care Options; MJH Associates; WebMD/Medscape
Consulting or Advisory Role - AstraZeneca; Exact Sciences
Research Funding - Carisma Therapeutics (Inst)
Travel, Accommodations, Expenses - Carisma Therapeutics
 
Paula R Pohlmann
Leadership - Immunonet BioSciences
Stock and Other Ownership Interests - Immunonet BioSciences
Honoraria - Dava Oncology; Frontiers Media; OncLive/MJH Life Sciences; SABCS
Consulting or Advisory Role - Abbvie; Bolt Biotherapeutics; Caris Life Sciences; HERON; Immunonet BioSciences; Juniper Pharmaceuticals; OncoPlex Diagnostics; Personalized Cancer Therapy; Pfizer; Pfizer; Puma Biotechnology; Sirtex Medical
Speakers' Bureau - Genentech/Roche
Research Funding - Advanced Cancer Therapeutics (Inst); Bolt Biotherapeutics (Inst); Byondis (Inst); Caris Centers of Excellence (Inst); Caris Centers of Excellence (Inst); Carisma Therapeutics (Inst); Cascadian Therapeutics (Inst); Fabre-Kramer (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Orum Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); SEAGEN (Inst); SEAGEN (Inst); SEAGEN (Inst)
Patents, Royalties, Other Intellectual Property - Patent application; United States Patent no. 8,486,413.; United States Patent no. 8,501,417; United States Patent no. 9,023,362; United States Patent no. 9,745,377
(OPTIONAL) Uncompensated Relationships - Jazz Pharmaceuticals; Pfizer; SEAGEN
 
Richard T. Maziarz
Leadership - Artiva
Honoraria - Novartis
Consulting or Advisory Role - incyte; Kite/Gilead; Novartis
Research Funding - Allovir; Bristol-Myers Squibb/Celgene/Juno; Gamida Cell; Novartis; ORCA Therapeutics
Patents, Royalties, Other Intellectual Property - ATHERSYS, INC shared patent re: use of mesenchymal stromal cells for treatment of GVHD
 
Hemant S. Murthy
Consulting or Advisory Role - CRISPR Therapeutics; Jazz Pharmaceuticals; Senti Biosciences
Research Funding - crispr therapeutics (Inst)
 
Yuan Yuan
Consulting or Advisory Role - AstraZeneca; Diiachi; Genentech; Merck; Stemline Therapeutics; Stemline Therapeutics
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Lilly; Gilead Sciences; Merck
Research Funding - Genentech; Imugene; Merck; Novartis; Pfizer
Expert Testimony - Novartis
 
Anuradha Krishnamurthy
No Relationships to Disclose
 
Kim Anna Reiss
Honoraria - MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Carisma Therapeutics; Foundation Medicine; Guardant Health
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology; GlaxoSmithKline (Inst); Lilly (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from invention (I)
 
James Isaacs
Research Funding - Bristol-Myers Squibb/Medarex (Inst); Merck (Inst); TScan Therapeutics (Inst)
 
Daniel Blumenthal
Employment - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
 
Linara Gabitova
Employment - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
 
Brett Menchel
Employment - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
 
Kenneth Locke
Employment - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
 
Jeanette Wetzel
No Relationships to Disclose
 
Michael Klichinsky
Employment - Carisma Therapeutics
Leadership - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
 
Daniel Cushing
Employment - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
 
Thomas Condamine
Employment - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
 
Davendra Sohal
Consulting or Advisory Role - AADi; AstraZeneca/MedImmune; Bayer; Elevar Therapeutics; Regeneron; Totus Medicines; TransThera Sciences (Nanjing), Inc.; Valar Labs
Speakers' Bureau - AstraZeneca; Incyte; Seagen
Research Funding - Ability Pharma (Inst); Amgen (Inst); Apexigen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bexion (Inst); Bristol-Myers Squibb (Inst); FibroGen (Inst); Genentech (Inst); Hengrui Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); NextCure (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Triumvira Immunologics, Inc (Inst)
Travel, Accommodations, Expenses - Ability Pharma